Insomnia Treatment Market

Global Insomnia Treatment Market Size, Share & Trends Analysis Report by Type (Drugs (Antidepressant, Benzodiazepine, Nonbenzodiazepine, Melatonin Receptor Agonist, Orexin Antagonist, and Others), and Devices), and by Sales Channels (Prescription and Over-the-Counter (OTC)), and Forecast 2020-2026
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2021810 | Category : Pharmaceuticals | Delivery Format: /

The global insomnia treatment market is projected to grow significantly during the forecast period. Insomnia is a sleep disorder that has been prevalent across the globe. Insomnia is also referred to as sleeplessness that disturbs the sleep cycle and creates distress in patients. Patients with this insomnia face difficulty in falling asleep or staying asleep for a long time. Insomnia leads to low energy, irritability, daytime sleepiness, and a depressed mood in patients that may affect concentration and ability to focus. 

Insomnia can occur due to mental stress, chronic pain, restless leg syndrome, menopause, and others. The increasing prevalence of insomnia primarily drives the growth of the market during the forecast. Some of the factors that lead to insomnia include excessive stress, eating too much late in the evening, and sleep apnea disorders. Primarily, insomnia can be treated by improving sleep hygiene and lifestyle. Sleep lifestyle may get better with consistent bedtime, a quiet and darkroom, exposure to sunlight, and regular exercise.

Further, the development of novel technologies and medical devices are also projected to propel the market growth. Medical devices such as Fisher Wallace Stimulator, Ebb Insomnia Therapy, and Alpha-Stim AID are some of the approved medical devices that are used for the treatment of insomnia. Thus, the adoption of drug and device combination therapies for treating insomnia is likely to boost the market growth over the forecast period.

Segmental Outlook

The global insomnia treatment market is segmented on the basis of type and sales channels. Based on the type, the market is segmented into drugs and devices. Drugs segment is further divided into antidepressant, benzodiazepine, nonbenzodiazepine, melatonin receptor agonist, orexin antagonist, and others. Based on the sales channels, the market is segmented as prescription and over-the-counter (OTC). 

Global Insomnia Treatment Market by Formulation, 2019 (%)

 Global Insomnia Treatment Market by Formulation

Drugs Segment Significantly Contribute to the Market Growth

Amongst the type of global insomnia treatment market, the drug segment is projected to contribute significantly to the market during the forecast period. Treatment is essential for insomnia, as the untreated disorder can result in serious health problems. Medications are given as the initial treatment for insomnia. Hypnotic, sedative, antihistamine, benzodiazepine, nonbenzodiazepine, melatonin receptor agonist, orexin antagonist, are some of the drug classes available for the insomnia treatment. 

Further, the availability of a wide range of drugs also drives the segmental growth of the market. For instance, Merck & Co. Inc. provides Belsomra (suvorexant), an orexin receptor antagonist indicated for the treatment of insomnia and sleep maintenance. Similarly, Sanofi SA provides Zolpidem, which is a sedative-hypnotic medication used to treat short term insomnia. Thus, these altogether drives the growth of the market. 

Regional Outlook

The global insomnia treatment market is geographically segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is projected to hold a considerable share in the market. This is attributed to the increased cases of insomnia recorded in the region. According to the National Center for Biotechnology Information, in the US population, 30% of adults suffer from insomnia and 10% from chronic insomnia. 

The increasing cases of sleep disorders have increased the demands for prescription drugs and medication for insomnia. Moreover, sleeping pills are one of the most prescribed drugs in the US. In the US, an estimated 50-70 million people are considered to be sleep deprived or have insomnia. According to the Centers for Disease Control and Prevention in 2019, around 4% of the US adults aged 20 and older used prescription sleep pills and women are more likely to use sleeping pills.

Global Insomnia Treatment Market, by Region 2019 (%)

 Global Insomnia Treatment Market by region

Market Players Outlook

Numerous major players are operating in the insomnia treatment industry. Some of the prominent players operating in the global insomnia treatment market include Arena Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Co., Merck & Co. Inc., Mylan N.V., Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and others. These are the key companies adopting several organic and inorganic growth strategies such as product launches & developments, partnerships, agreements, and acquisitions to strengthen their product portfolios and maintain a competitive position in the global insomnia treatment market. 

The Report Covers

  • Market value data analysis of 2019 and forecast to 2026.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global insomnia treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.

1. Report Summary

1.1. Research Methods and Tools

1.2. Market Breakdown

1.2.1. By Segments

1.2.2. By Geography

2. Market Overview and Insights

2.1. Scope of the Report

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

2.3. Rules & Regulations

3. Competitive Landscape

3.1. Key Strategy Analysis

3.2. Key Company Analysis

3.2.1. Pfizer Inc.

3.2.1.1. Overview

3.2.1.2. Financial Analysis 

3.2.1.3. SWOT Analysis

3.2.1.4. Recent Developments

3.2.2. Sanofi SA

3.2.2.1. Overview

3.2.2.2. Financial Analysis 

3.2.2.3. SWOT Analysis

3.2.2.4. Recent Developments

3.2.3. Merck & Co. Inc.

3.2.3.1. Overview

3.2.3.2. Financial Analysis 

3.2.3.3. SWOT Analysis

3.2.3.4. Recent Developments

3.2.4. Takeda Pharmaceuticals Co. Ltd.

3.2.4.1. Overview

3.2.4.2. Financial Analysis 

3.2.4.3. SWOT Analysis

3.2.4.4. Recent Developments

3.2.5. Boehringer Ingelheim International GmbH

3.2.5.1. Overview

3.2.5.2. Financial Analysis 

3.2.5.3. SWOT Analysis

3.2.5.4. Recent Developments

4. Market Determinants

4.1. Motivators

4.2. Restraints

4.3. Opportunities

5. Market Segmentation

5.1. Global Insomnia Treatment Market by Type 

5.1.1. Drugs

5.1.1.1. Antidepressants

5.1.1.2. Benzodiazepine

5.1.1.3. Nonbenzodiazepine

5.1.1.4. Melatonin Receptor Agonist

5.1.1.5. Orexin Antagonist

5.1.1.6. Others

5.1.2. Devices

5.2. Global Insomnia Treatment Market by Sales Channels

5.2.1. Prescription

5.2.2. Over-the-Counter (OTC)

6. Regional Analysis

6.1. North America

6.1.1. United States

6.1.2. Canada

6.2. Europe

6.2.1. UK

6.2.2. Germany

6.2.3. Italy

6.2.4. Spain

6.2.5. France

6.2.6. Rest of Europe 

6.3. Asia-Pacific

6.3.1. China

6.3.2. India

6.3.3. Japan

6.3.4. Rest of Asia-Pacific 

6.4. Rest of the World

7. Company Profiles

7.1. Arena Pharmaceuticals, Inc. 

7.2. Boehringer Ingelheim International GmbH

7.3. Eisai Co. Ltd.

7.4. Electromedical Products International Inc.

7.5. Eli Lilly and Co.

7.6. GlaxoSmithKline Plc

7.7. Mallinckrodt LLC

7.8. Merck & Co. Inc.

7.9. Mylan N.V.

7.10. Natrol, LLC

7.11. Paratek Pharmaceuticals Inc.

7.12. Pfizer Inc.

7.13. Sanofi SA

7.14. Sumitomo Dainippon Pharma Co. Ltd.

7.15. Takeda Pharmaceutical Co. Ltd.

7.16. Teva Pharmaceutical Industries Ltd.

7.17. Vanda Pharmaceuticals Inc.

1. GLOBAL INSOMNIA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)

2. GLOBAL INSOMNIA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

3. GLOBAL ANTIDEPRESSANT DRUGS FOR INSOMNIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

4. GLOBAL BENZODIAZEPINE DRUGS FOR INSOMNIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

5. GLOBAL NONBENZODIAZEPINE DRUGS FOR INSOMNIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

6. GLOBAL MELATONIN RECEPTOR AGONIST DRUGS FOR INSOMNIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

7. GLOBAL OREXIN ANTAGONIST DRUGS FOR INSOMNIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

8. GLOBAL OTHER DRUGS FOR INSOMNIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

9. GLOBAL DEVICES FOR INSOMNIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

10. GLOBAL INSOMNIA TREATMENT MARKET RESEARCH AND ANALYSIS BY SALES CHANNEL, 2019-2026 ($ MILLION)

11. GLOBAL PRESCRIPTION TREATMENT FOR INSOMNIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

12. GLOBAL OVER-THE-COUNTER (OTC) TREATMENT FOR INSOMNIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

13. GLOBAL INSOMNIA TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)

14. NORTH AMERICAN INSOMNIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)

15. NORTH AMERICAN INSOMNIA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)

16. NORTH AMERICAN INSOMNIA TREATMENT MARKET RESEARCH AND ANALYSIS BY SALES CHANNEL, 2019-2026 ($ MILLION)

17. EUROPEAN INSOMNIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)

18. EUROPEAN INSOMNIA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)

19. EUROPEAN INSOMNIA TREATMENT MARKET RESEARCH AND ANALYSIS BY SALES CHANNEL, 2019-2026 ($ MILLION)

20. ASIA-PACIFIC INSOMNIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)

21. ASIA-PACIFIC INSOMNIA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)

22. ASIA-PACIFIC INSOMNIA TREATMENT MARKET RESEARCH AND ANALYSIS BY SALES CHANNEL, 2019-2026 ($ MILLION)

23. REST OF THE WORLD INSOMNIA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)

24. REST OF THE WORLD INSOMNIA TREATMENT MARKET RESEARCH AND ANALYSIS BY SALES CHANNEL, 2019-2026 ($ MILLION)

1. GLOBAL INSOMNIA TREATMENT MARKET SHARE BY TYPE, 2019 VS 2026 (%)

2. GLOBAL INSOMNIA TREATMENT MARKET SHARE BY SALES CHANNEL, 2019 VS 2026 (%)

3. GLOBAL INSOMNIA TREATMENT MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)

4. US INSOMNIA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)

5. CANADA INSOMNIA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)

6. UK INSOMNIA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)

7. FRANCE INSOMNIA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)

8. GERMANY INSOMNIA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)

9. ITALY INSOMNIA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)

10. SPAIN INSOMNIA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)

11. ROE INSOMNIA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)

12. INDIA INSOMNIA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)

13. CHINA INSOMNIA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)

14. JAPAN INSOMNIA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)

15. REST OF ASIA-PACIFIC INSOMNIA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)

16. REST OF THE WORLD INSOMNIA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)